CD274 and neoplasm: Both the nivolumab + chemotherapy group (n = 321) and the nivolumab + ipilimumab group (n = 325) achieved significantly longer median OS than the chemotherapy alone group (n = 324) in patients with tumor cell PD-L1 expression of 1 or greater (15.4 months vs. 13.7 months vs. 9.1 months, respectively; p < 0.001 for nivolumab + chemotherapy vs. chemotherapy, p = 0.001 for nivolumab + ipilimumab vs. chemotherapy).